The effective treatment of COPD: Anticholinergics and what else?

Drug Discovery Today: Therapeutic Strategies

Volumn 3, Issue 3, 2006, Pages 277-286

  Cazzola, Mario ^a   Matera, Maria Gabriella ^b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ARFORMOTEROL; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CARMOTEROL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; GSK 159797; GSK 159802; GSK 233705; GSK 597901; GSK 678007; GSK 685698; GW 642444; INDACATEROL; MUSCARINIC RECEPTOR BLOCKING AGENT; NITRIC OXIDE SYNTHASE INHIBITOR; NVA 237; PHOSPHODIESTERASE IV INHIBITOR; SALBUTAMOL; SALMETEROL; THEOPHYLLINE; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ASTHMA; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENTIATION; FORCED EXPIRATORY VOLUME; HUMAN; INHALER; LUNG FUNCTION; MONOTHERAPY; QUALITY OF LIFE; RESPIRATORY TRACT DISEASE; REVIEW; SYMPTOM; TREATMENT OUTCOME;

EID: 33751193695     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2006.09.009     Document Type: Review

References (39)

1. Celli B.R., and MacNee W. ATS/ERS task force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur. Respir. J. 23 (2004) 932-946
2. Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 59 Suppl. 1 (2004) 1-232
3. Global Initiative for Chronic Obstructive Lung Disease. (2005) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease - 2005 update. Available at: http://www.goldcopd.com/ (accessed July 7, 2006).
4. Barnes P.J. The role of anticholinergics in chronic obstructive pulmonary disease. Am. J. Med. 117 Suppl. 12A (2004) 24S-32S
5. Cazzola M., and Matera M.G. Long-acting bronchodilators are the first-choice option for the treatment of stable COPD. Chest 125 (2004) 9-11
6. Rodrigo G.J., and Nannini L.J. Tiotropium for the treatment of stable chronic obstructive pulmonary disease: A systematic review with meta-analysis. Pulm. Pharmacol. Ther. (2006) 10.1016/j.pupt.2006.02.003 (Epub ahead of print)
7. Currie G.P., et al. Effects of tiotropium and other long acting bronchodilators in chronic obstructive pulmonary disease. Pulm. Pharmacol. Ther. 19 (2006) 112-119
8. Adams S.G., et al. Tiotropium in COPD patients not previously receiving maintenance respiratory medications. Respir. Med. (2006) 10.1016/j.rmed.2006.03.034 (Epub ahead of print)
9. Belvisi M.G., et al. Paradoxical facilitation of acetylcholine release from parasympathetic nerves innervating guinea-pig trachea by isoprenaline. Br. J. Pharmacol. 117 (1996) 1413-1420
10. Richter K., et al. Onset and duration of action of formoterol and tiotropium in patients with moderate to severe COPD. Respiration 73 (2006) 414-419
11. Cazzola M., et al. The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pulm. Pharmacol. Ther. 17 (2004) 35-39
12. van Noord J.A., et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur. Respir. J. 26 (2005) 214-222
13. van Noord J.A., et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 129 (2006) 509-517
14. Cazzola M., et al. Bronchodilator response to formoterol after regular tiotropium or to tiotropium after regular formoterol in COPD patients. Respir. Med. 99 (2005) 524-528
15. Cazzola M., et al. The functional impact of adding salmeterol and tiotropium in patients with stable COPD. Respir. Med. 98 (2004) 1214-1221
16. Di Marco F., et al. Effect of formoterol, tiotropium, and their combination in patients with acute exacerbation of chronic obstructive pulmonary disease: a pilot study. Respir. Med. (2006) 10.1016/j.rmed.2005.10.008 (Epub ahead of print)
17. Barnes P.J. Chronic obstructive pulmonary disease. N. Engl. J. Med. 343 (2000) 269-280
18. Culpitt S.V., et al. Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 160 (1999) 1635-1639
19. Sin D.D., et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 60 (2005) 992-997
20. 2-agonists and corticosteroids in stable COPD. Chest 126 (2004) 220-237
21. 2-agonists in the prevention of exacerbations in COPD. Intern. J. COPD (in press).
22. van Schayck C.P., and Reid J. Effective management of COPD in primary care - the role of long-acting beta agonist/inhaled corticosteroid combination therapy. Prim. Care Respir. J. 15 (2006) 143-151
23. Barnes P.J. Reduced histone deacetylase in COPD: clinical implications. Chest 129 (2006) 151-155
24. Cazzola M., et al. Salmeterol/fluticasone propionate in a single inhaler device versus theophylline + fluticasone propionate in patients with COPD. Pulm. Pharmacol. Ther. 17 (2004) 141-145
25. Decramer M., et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 365 (2005) 1552-1560
26. Matera M.G., and Cazzola M. New anti-inflammatory approaches in COPD. Drug. Discov. Today: Ther. Strat. 1 (2004) 335-343
27. 2-agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin. Investig. Drugs 14 (2005) 775-783
28. FDA Public Health Advisory. (2006) Serevent Diskus (salmeterol xinafoate inhalation powder), Advair Diskus (fluticasone propionate & salmeterol inhalation powder), Foradil Aerolizer (formoterol fumarate inhalation powder). http://www.fda.gov/cder/drug/advisory/LABA.htm (accessed May 28, 2006)
29. 2-agonist carmoterol and tiotropium bromide in the control of airway changes induced by different challenges in guinea-pigs. Pulm. Pharmacol. Ther. (2006) 10.1016/j.pupt.2006.01.004 (Epub ahead of print)
30. Cooper N., et al. NVA237 and tiotropium bromide demonstrate similar efficacy in an anesthetized rabbit model of methacholine-induced bronchoconstriction. NVA237 demonstrates a reduced systemic pharmacological effect on cardiovascular parameters. Proc. Am. Thor. Soc. 3 (2006) A117 (Abstract)
31. Thomas R., et al. Low systemic exposure of NVA237, an inhaled once-daily antimuscarinic bronchodilator, in healthy human volunteers. Proc. Am. Thor. Soc. 3 (2006) A725 (Abstract)
32. Gunawardena K.A., et al. NVA237, a once-daily antimuscarinic, demonstrates sustained bronchodilation and is well tolerated in patients with reversible obstructive airways disease. Proc. Am. Thor. Soc. 3 (2006) A117 (Abstract)
33. Singh D., et al. NVA237, a once-daily inhaled antimuscarinic, provides 24-hour bronchodilator efficacy with comparable bronchodilation to albuterol in patients with moderate-to-severe COPD. Proc. Am. Thor. Soc. 3 (2006) A113 (Abstract)
34. Lu S., et al. An oral selective M3 anticholinergic receptor antagonist in COPD. Eur. Respir. J. (2006) 10.1183/09031936.06.00126005 (Epub ahead of print)
35. Boswell-Smith V., et al. Are phosphodiesterase 4 inhibitors just more theophylline?. J. Allergy Clin. Immunol. 117 (2006) 1237-1243
36. Rabe K.F., et al. Roflumilast - an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 366 (2005) 563-571
37. Rennard S.I., et al. Results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4. Chest 129 (2006) 565-566
38. Grootendorst C., et al. Treatment with PDE4 inhibitor roflumilast reduces sputum neutrophil and eosinophil numbers in patients with COPD. Proc. Am. Thor. Soc. 2 (2005) A543 (Abstract)
39. Martorana P.A., et al. Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke. Am. J. Respir. Crit. Care Med. 172 (2005) 848-853